205 related articles for article (PubMed ID: 24558415)
1. Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.
Xu F; Li X; Chang CK; Guo J; Wu LY; He Q; Zhang Z; Zhu Y; Gu SC; Shi WH; Song LX; Su JY; Zhou LY; Zhang X; Wu D
PLoS One; 2014; 9(2):e88706. PubMed ID: 24558415
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
[TBL] [Abstract][Full Text] [Related]
4. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
[TBL] [Abstract][Full Text] [Related]
5. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
[TBL] [Abstract][Full Text] [Related]
7. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes.
Gardikas N; Vikentiou M; Konsta E; Kontos CK; Papageorgiou SG; Spathis A; Bazani E; Bouchla A; Kapsimali V; Psarra K; Foukas P; Dimitriadis G; Pappa V
Cytometry B Clin Cytom; 2019 Jan; 96(1):73-82. PubMed ID: 30334347
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].
Xu J; Zhang W; Liu Y; Wan SG; Sun XJ; Zhao H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1477-81. PubMed ID: 20030930
[TBL] [Abstract][Full Text] [Related]
10. [Role of flow cytometric immunophenotyping in diagnosis of myelodysplastic syndromes--review].
Zhang Y; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1477-81. PubMed ID: 19099668
[TBL] [Abstract][Full Text] [Related]
11. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.
Reis-Alves SC; Traina F; Harada G; Campos PM; Saad ST; Metze K; Lorand-Metze I
PLoS One; 2013; 8(12):e81048. PubMed ID: 24324660
[TBL] [Abstract][Full Text] [Related]
13. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes.
Xu F; Wu L; He Q; Zhang Z; Chang C; Li X
Intern Med J; 2012 Apr; 42(4):401-11. PubMed ID: 22032631
[TBL] [Abstract][Full Text] [Related]
15. The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study.
Chauhan R; Singh J; Sharma C; Dange P; Chopra A; Mahapatra M; Pati H
Leuk Res; 2021 Aug; 107():106651. PubMed ID: 34218155
[TBL] [Abstract][Full Text] [Related]
16. Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia.
Tang G; Jorgensen LJ; Zhou Y; Hu Y; Kersh M; Garcia-Manero G; Medeiros LJ; Wang SA
Leuk Res; 2012 Aug; 36(8):974-81. PubMed ID: 22626984
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes.
Davydova YO; Parovichnikova EN; Galtseva IV; Kokhno AV; Dvirnyk VN; Kovrigina AM; Obukhova TN; Kapranov NM; Nikiforova KA; Glinkina SA; Troitskaya VV; Mikhailova EA; Fidarova ZT; Moiseeva TN; Lukina EA; Tsvetaeva NV; Nikulina OF; Kuzmina LA; Savchenko VG
Cytometry B Clin Cytom; 2021 May; 100(3):312-321. PubMed ID: 33052634
[TBL] [Abstract][Full Text] [Related]
18. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
van de Loosdrecht AA; Alhan C; Béné MC; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Homburg CH; Ireland R; Jansen JH; Kern W; Malcovati L; Te Marvelde JG; Mufti GJ; Ogata K; Orfao A; Ossenkoppele GJ; Porwit A; Preijers FW; Richards SJ; Schuurhuis GJ; Subirá D; Valent P; van der Velden VH; Vyas P; Westra AH; de Witte TM; Wells DA; Loken MR; Westers TM
Haematologica; 2009 Aug; 94(8):1124-34. PubMed ID: 19546437
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic flow cytometry for low-grade myelodysplastic syndromes.
Ogata K
Hematol Oncol; 2008 Dec; 26(4):193-8. PubMed ID: 18412289
[TBL] [Abstract][Full Text] [Related]
20. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome.
Chung JW; Park CJ; Cha CH; Cho YU; Jang S; Chi HS; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
Ann Clin Lab Sci; 2012; 42(3):271-80. PubMed ID: 22964615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
